Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences

Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma Patients” study examined real-world factors influencing treatment decisions, highlighting the significant role of survivorship burden and patient preferences, and emphasizing how these findings should shape the management strategies for patients with multiple myeloma.

EP: 1.Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024

EP: 2.Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making

Now Viewing

EP: 3.Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences

Video content above is prompted by the following:

• Discuss the data that were presented at the 2024 ASH Annual Meeting titled in “Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma (MM) Patients: Real-World Learnings from a Large, Prospective Study.”
• What was the objective of the study?
• How was this study designed/what methodology was used?
• What results were presented?
• What are your key takeaways from this study, and how do these results impact how you manage patients with MM?

Related Videos

Related Content

Advertisement

January 10th 2025

Ibrutinib Safe and Effective in Patients With CLL/SLL, Real-World Data Show

Karen Jacobson-Sive

The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 3rd 2025

New Generation of CAR T May Elicit Improved CR Rates in CLL

AJMC Contributor

A third-generation chimeric antigen receptor (CAR) T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

January 2nd 2025

BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024

Mary Caffrey

This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.

December 26th 2024

Top 5 Most-Read CLL/SLL Articles of 2024

Christina Mattina

This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment efficacy, and more.

December 26th 2024

ICYMI: Highlights From AMCP Nexus 2024

Kyle Munz

Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.

Related Content

Advertisement

January 10th 2025

Ibrutinib Safe and Effective in Patients With CLL/SLL, Real-World Data Show

Karen Jacobson-Sive

The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 3rd 2025

New Generation of CAR T May Elicit Improved CR Rates in CLL

AJMC Contributor

A third-generation chimeric antigen receptor (CAR) T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

January 2nd 2025

BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024

Mary Caffrey

This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.

December 26th 2024

Top 5 Most-Read CLL/SLL Articles of 2024

Christina Mattina

This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment efficacy, and more.

December 26th 2024

ICYMI: Highlights From AMCP Nexus 2024

Kyle Munz

Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.